Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
Part of paid clinical trials in Morrisville, North Carolina.
- Sponsor
- Mainz Biomed
- Study ID
- NCT06864338
- Status
- Recruiting
Conditions
- Colon Adenocarcinoma
- Colorectal Cancer Metastatic
- Colorectal Cancer Screening
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The Mainz Biomed Colorectal Cancer Screening Test is being studied for its performance in the identification of the presence of colorectal cancer (CRC) or advanced adenoma (AA) in the colon in patients at average risk for colorectal cancer.
Key Dates
- Start date
- Dec 18, 2022
- Status verified
- Jun 2025
- Primary completion
- Nov 30, 2025
- Completion
- Nov 30, 2025
Study Design
- Enrollment
- 2,700 participants (estimated)
Arms
- Arm: Individuals aged 45 and over at average risk of colorectal cancer.Individuals aged 45 and older that are advised to have or are scheduled for a screening colonoscopy and are at average risk for colorectal cancer.
- Arm: Individuals aged 18 and older suspected or known to have at least one precancerous, intact lesion.Individuals aged 18 and older that are suspected to have at least one advanced precancerous lesion or colorectal cancer. Subjects in this group are those that have been pre-identified with imaging, a positive non-invasive screening test, and/or colonoscopy which requires additional intervention.
Primary Outcome Measure
Feasibility, test optimization, algorithm, and cut off ranges for the Mainz Biomed Colorectal Cancer Screening Test. [ Time Frame: 3 years ]
Central Contacts
- Lena Krammes, PhD+49 (0) 613126514-18
- Christian Von Toerne, PhD+49 (0) 173 1621928
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Virtual Research Group | Morrisville | North Carolina | 27560 | Omar Matuk-Villazon, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Morrisville, NC
By research site
Related Studies
- Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon AdenocarcinomasPHASE1 · Recruiting · University of California, Irvine · Orange, California
- Living Donor Liver Transplant for Unresectable Colorectal Liver MetastasesRecruiting · University of Rochester · Rochester, New York
- Evaluating Novel Therapies in ctDNA Positive GI CancersPHASE3 · Recruiting · Georgetown University · Washington D.C., District of Columbia
- Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care SettingsEnrolling By Invitation · Rutgers, The State University of New Jersey · New Brunswick, New Jersey